TLDR
- AbCellera stock jumped 32% to $9.12 after its menopause drug ABCL635 met primary endpoints in a Phase 2 trial
- A single 600mg dose of ABCL635 reduced hot flash frequency by 8.8 events per day versus 3.5 for placebo
- The drug also reduced symptom severity and improved sleep quality in trial participants
- The trial enrolled 92 postmenopausal women and was randomized, double-blind, and placebo-controlled
- No serious adverse events were reported during the four-week treatment period
AbCellera (ABCL) stock jumped 32% to $9.12 on Monday after its experimental menopause drug posted strong Phase 2 results.
AbCellera Biologics Inc., ABCL
The stock had already more than doubled in 2026 heading into Monday, driven largely by anticipation for this data readout.
ABCL635 is a non-hormonal, long-acting treatment given as a single subcutaneous injection. It targets the neurokinin 3 receptor, which plays a role in triggering hot flashes.
The Phase 2 trial enrolled 92 postmenopausal women who were experiencing around 10 moderate or severe hot flashes per day. Participants received either a single 600mg subcutaneous dose of ABCL635 or a placebo.
The trial met its primary efficacy endpoints at week four. That means the drug hit the pre-set statistical targets the company needed to clear to call the study a success.
What the Numbers Show
On hot flash frequency, ABCL635 reduced moderate-to-severe episodes by 8.8 events per day from baseline. The placebo group saw a reduction of 3.5. That gives a placebo-adjusted treatment difference of 5.3 events per day.
On severity, the drug reduced scores by 1.4 points at week four compared to 0.3 for placebo, a placebo-adjusted difference of 1.1 points.
Patients taking ABCL635 also reported better sleep and an overall improvement in how they felt, based on the patient global impression of change measure.
The trial was randomized, double-blind, and placebo-controlled, which is the standard design for this type of study.
Safety Profile
The drug was well-tolerated over the four-week period. There were no serious adverse events, no severe adverse events, and no patients stopped the study due to side effects.
The most common side effects in the ABCL635 group were headache, fatigue, and injection site reaction.
AbCellera held a conference call Monday to discuss the results with investors and analysts.
The company is positioning ABCL635 as a non-hormonal option, which could matter for patients who cannot or prefer not to use hormone-based treatments.
ABCL stock closed at $9.12 on Monday, up 32% on the session.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
